WO2012120535A3 - Composition contenant de la gonadotropine chorionique extrêmement purifiée, sa formulation et ses utilisations - Google Patents

Composition contenant de la gonadotropine chorionique extrêmement purifiée, sa formulation et ses utilisations Download PDF

Info

Publication number
WO2012120535A3
WO2012120535A3 PCT/IN2012/000085 IN2012000085W WO2012120535A3 WO 2012120535 A3 WO2012120535 A3 WO 2012120535A3 IN 2012000085 W IN2012000085 W IN 2012000085W WO 2012120535 A3 WO2012120535 A3 WO 2012120535A3
Authority
WO
WIPO (PCT)
Prior art keywords
highly purified
composition
formulation
same
chorionic gonadotropin
Prior art date
Application number
PCT/IN2012/000085
Other languages
English (en)
Other versions
WO2012120535A2 (fr
Inventor
Prasad K.V.S.
L. Soman JAY
Original Assignee
Sanzyme Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanzyme Limited filed Critical Sanzyme Limited
Publication of WO2012120535A2 publication Critical patent/WO2012120535A2/fr
Publication of WO2012120535A3 publication Critical patent/WO2012120535A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une composition contenant une faible dose de gonadotropine chorionique humaine (hCG) sous une forme extrêmement purifiée destinée à une nouvelle application visant à favoriser l'environnement oestrogénique pour soutenir la croissance et la réceptivité endométriales, ainsi que la croissance folliculaire avec ou sans préparation concomitante d'hormone de stimulation folliculaire (FSH). La composition contient la gonadotropine chorionique humaine (hCG) extrêmement purifiée dans une dose allant de 100 IU à 200 IU.
PCT/IN2012/000085 2011-02-03 2012-02-03 Composition contenant de la gonadotropine chorionique extrêmement purifiée, sa formulation et ses utilisations WO2012120535A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN315MU2011 2011-02-03
IN315/MUM/2011 2011-02-03

Publications (2)

Publication Number Publication Date
WO2012120535A2 WO2012120535A2 (fr) 2012-09-13
WO2012120535A3 true WO2012120535A3 (fr) 2013-03-14

Family

ID=46798607

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000085 WO2012120535A2 (fr) 2011-02-03 2012-02-03 Composition contenant de la gonadotropine chorionique extrêmement purifiée, sa formulation et ses utilisations

Country Status (1)

Country Link
WO (1) WO2012120535A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060217315A1 (en) * 2001-12-21 2006-09-28 Coelingh Bennink Herman J T Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
US7297777B2 (en) * 2000-02-22 2007-11-20 Laboratoires Serono Sa Process of purification of hCG and recombinant hCG purified by that method
US20080119394A1 (en) * 2003-06-03 2008-05-22 Ferring B.V. Unitary Combinations of FSH and hCG

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297777B2 (en) * 2000-02-22 2007-11-20 Laboratoires Serono Sa Process of purification of hCG and recombinant hCG purified by that method
US20060217315A1 (en) * 2001-12-21 2006-09-28 Coelingh Bennink Herman J T Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
US20080119394A1 (en) * 2003-06-03 2008-05-22 Ferring B.V. Unitary Combinations of FSH and hCG

Also Published As

Publication number Publication date
WO2012120535A2 (fr) 2012-09-13

Similar Documents

Publication Publication Date Title
WO2012127501A3 (fr) Composition pour améliorer l'épaisseur endométriale au cours de la stimulation ovarienne
WO2014066468A8 (fr) Formulation d'anticorps, stable, à faible viscosité
BR112014003462A2 (pt) artigos para cuidados pessoais tendo múltiplas zonas com composições para cuidados pessoais maleáveis
EP4219560A3 (fr) Anticorps neutralisant l'intégrine alpha v bêta 8
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
WO2010000877A3 (fr) Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations
BR112014004460A2 (pt) material polimérico para um recipiente isolado
AR086237A1 (es) FORMULACION PARA ANTICUERPO ANTI-a4b7
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
WO2014141152A3 (fr) Formulations d'anticorps à faibles concentrations
BR112012021337A2 (pt) formulações de apixaban.
WO2010149980A3 (fr) Préparation topique contenant une tétracycline et méthode de traitement des infections de la peau utilisant cette préparation
GT200500045A (es) Solidos supersaturados estabilizados de drogas lipofilicas
WO2013126387A3 (fr) Composition
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2010030598A3 (fr) Formulations pharmaceutiques comprenant du pemetrexed
MX339060B (es) Formulaciones del factor viii.
WO2011160024A3 (fr) Composés utiles en tant qu'agents antiviraux, compositions, et procédés d'utilisation
WO2012051407A3 (fr) Contenants moléculaires ainsi que leurs méthodes de fabrication et d'utilisation
NZ598518A (en) Concentrated polypeptide formulations with reduced viscosity
GT200800117A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y uso
BR112014030700A2 (pt) formulações em spray com características reduzidas de obstrução/sedimentação
WO2011039369A3 (fr) Formes amorphes d'un dérivé de 2-amino-4-(4-fluorobenzylamino)phénylcarbamate
WO2011002422A3 (fr) Formulation pharmaceutique améliorant la solubilité
CL2012003497A1 (es) Procedimiento para preparar el compuesto diácido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico cristalino; su uso para preparar una formulación galénica del complejo de gadolinio de diacido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico; y el compuesto con una pureza superior al 99%.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12755077

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12755077

Country of ref document: EP

Kind code of ref document: A2